Pfizer Inc. (0Q1N.L)
- Business Wire
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
NEW YORK, April 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
- Yahoo Finance Video
Pfizer unveils positive phase 3 trial results for RSV vaccine
Pfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older. Yahoo Finance's Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. Editor's note: This article was written by Angel Smith
- Business Wire
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
NEW YORK, April 09, 2024--Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
